The FDA on April 23, 2024, the Food and Drug Administration granted accelerated approval to OJEMDA® (Tovorafenib) for patients 6 months of age and older with relapsed or refractory pediatric Low-Grade Glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. OJEMDA® is a product of Day One Biopharmaceuticals, Inc.
Bottom Ad
Advertisement
Subscribe
